UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study

Journal of psychopharmacology (Oxford), 2022-06, Vol.36 (6), p.745-755

2022

Volltextzugriff (PDF)

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

Sleep (New York, N.Y.), 2019-04, Vol.42 (4), p.1

2019

Volltextzugriff (PDF)

Type Synthesis of 5-DOF Hybrid (Parallel-Serial) Manipulators Designed from Open Kinematic Chains

Robotics (Basel), 2023-08, Vol.12 (4), p.98

2023

Volltextzugriff (PDF)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant

Pharmacology research & perspectives, 2021-04, Vol.9 (2), p.e00758-n/a

2021

Volltextzugriff (PDF)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant

Pharmacology research & perspectives, 2021-04, Vol.9 (2), p.e00734-n/a

2021

Volltextzugriff (PDF)

P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD‐ON DANICOPAN VS PLACEBO

HemaSphere, 2023-08, Vol.7 (S3), p.e777903c-n/a

2023

Volltextzugriff (PDF)

Role of cyclophilin D in the resistance of brain mitochondria to the permeability transition

Neurobiology of aging, 2007-10, Vol.28 (10), p.1532-1542

2007

Volltextzugriff (PDF)

Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2

Sleep (New York, N.Y.), 2020-09, Vol.43 (9), p.1

2020

Volltextzugriff (PDF)

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users

Journal of clinical psychopharmacology, 2022-07, Vol.42 (4), p.365-373

2022

Volltextzugriff (PDF)

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial

JAMA network open, 2019-12, Vol.2 (12), p.e1918254-e1918254

2019

Volltextzugriff (PDF)

Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial

Sleep medicine, 2021-04, Vol.80, p.333-342

2021

Volltextzugriff (PDF)

Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study

Current medical research and opinion, 2015-04, Vol.31 (4), p.785-794

2015

Volltextzugriff (PDF)

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users

Journal of clinical psychopharmacology, 2022-07, Vol.42 (4), p.374-382

2022

Volltextzugriff (PDF)

Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double‐blind, placebo‐controlled, crossover study

Journal of sleep research, 2020-08, Vol.29 (4), p.e13021-n/a

2020

Volltextzugriff (PDF)

Impact of Lemborexant Treatment on Insomnia Disease Severity and Fatigue: Results from the 12-Month Phase 3 Study SUNRISE-2 (112)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Effectiveness and Safety of Lemborexant Over 12 Months in Adults with Insomnia Disorder: Longterm Results From the Phase 3 SUNRISE-2 Study (420)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

MOMENTUM (Study 304; NCT04572243): A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Adjunctive Lorcaserin in Patients with Dravet Syndrome (DS) (1612)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

Blood, 2023-11, Vol.142 (Supplement 1), p.576-576

2023

Volltextzugriff (PDF)

0430 Respiratory Safety of Lemborexant in Healthy Adult and Elderly Subjects

Sleep (New York, N.Y.), 2019-04, Vol.42 (Supplement_1), p.A174-A174

2019

Volltextzugriff (PDF)

0429 Respiratory Safety of Lemborexant in Adult and Elderly Subjects with Mild Obstructive Sleep Apnea

Sleep (New York, N.Y.), 2019-04, Vol.42 (Supplement_1), p.A173-A174

2019

Volltextzugriff (PDF)

0367 Lemborexant Treatment for Insomnia: 6-month Safety

Sleep (New York, N.Y.), 2019-04, Vol.42 (Supplement_1), p.A149-A150

2019

Volltextzugriff (PDF)

Efficacy and Safety of Lemborexant Across 12 Months in Elderly Subjects With Insomnia Disorder

Journal of the National Medical Association, 2020-10, Vol.112 (5), p.S27-S27

2020

Volltextzugriff (PDF)

Efficacy and Safety of Lemborexant in Subjects Previously Randomized to Placebo for 6 Months

Journal of the National Medical Association, 2020-10, Vol.112 (5), p.S27-S27

2020

Volltextzugriff (PDF)

SAFETY OF LEMBOREXANT IN ELDERLY SUBJECTS WITH INSOMNIA: RESULTS FROM A PHASE 3 STUDY (SUNRISE 1)

The American journal of geriatric psychiatry, 2019-03, Vol.27 (3), p.S196-S197

2019

Volltextzugriff (PDF)

165 Impact of Lemborexant on Insomnia Disease Severity and Fatigue: Results from the 6-Month Placebo-Controlled Period of the Phase 3 SUNRISE-2 Study

CNS spectrums, 2020-04, Vol.25 (2), p.305-306

2020

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(62)

Publikationsform

Sprache

Englisch
(83)
Russisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

Type Synthesis of 5-DOF Hybrid (Parallel-Serial) Manipulators Designed from Open Kinematic Chains

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant

P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD‐ON DANICOPAN VS PLACEBO

Role of cyclophilin D in the resistance of brain mitochondria to the permeability transition

Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial

Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial

Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users

Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double‐blind, placebo‐controlled, crossover study

Impact of Lemborexant Treatment on Insomnia Disease Severity and Fatigue: Results from the 12-Month Phase 3 Study SUNRISE-2 (112)

Effectiveness and Safety of Lemborexant Over 12 Months in Adults with Insomnia Disorder: Longterm Results From the Phase 3 SUNRISE-2 Study (420)

MOMENTUM (Study 304; NCT04572243): A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Adjunctive Lorcaserin in Patients with Dravet Syndrome (DS) (1612)

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

0430 Respiratory Safety of Lemborexant in Healthy Adult and Elderly Subjects

0429 Respiratory Safety of Lemborexant in Adult and Elderly Subjects with Mild Obstructive Sleep Apnea

0367 Lemborexant Treatment for Insomnia: 6-month Safety

Efficacy and Safety of Lemborexant Across 12 Months in Elderly Subjects With Insomnia Disorder

Efficacy and Safety of Lemborexant in Subjects Previously Randomized to Placebo for 6 Months

SAFETY OF LEMBOREXANT IN ELDERLY SUBJECTS WITH INSOMNIA: RESULTS FROM A PHASE 3 STUDY (SUNRISE 1)

165 Impact of Lemborexant on Insomnia Disease Severity and Fatigue: Results from the 6-Month Placebo-Controlled Period of the Phase 3 SUNRISE-2 Study

Suchergebnisse filtern